Catechin polyphenols: Neurodegeneration and neuroprotection in neurodegenerative diseases

Free Radical Biology and Medicine

Volumn 37, Issue 3, 2004, Pages 304-317

  Mandel, Silvia ^a   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

synuclein; Alzheimer's disease; Antioxidant; Bcl 2 family proteins; Cell signaling; Free radicals; Green tea catechins; Iron; Iron chelating; Neurodegenerative diseases; Neuroprotection; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALZHEIMER DISEASE VACCINE; ANTIOXIDANT; CATECHIN; ENTACAPONE; EPICATECHIN; EPIGALLOCATECHIN GALLATE; FLAVONOID; GINKGO BILOBA EXTRACT; GREEN TEA EXTRACT; IRON; MELATONIN; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; POLYPHENOL DERIVATIVE; PROTEASOME; PROTEIN KINASE C; RASAGILINE; SCAVENGER; SELEGILINE; TOLCAPONE; UBIQUITIN;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CELL CULTURE; CELL DEATH; CELL SURVIVAL; CLINICAL TRIAL; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; GENE ACTIVATION; GENE EXPRESSION; HUMAN; INFLAMMATION; IRON CHELATION; MEMBRANE PERMEABILITY; MITOCHONDRION; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; TEA;

ANIMALS; CATECHIN; FLAVONOIDS; HUMANS; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PHENOLS; TEA;

LETHRINIDAE;

EID: 3042667647     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2004.04.012     Document Type: Review

References (135)

1. Gerlach M., Double K.L., Ben-Shachar D., Zecca L., Youdim M.B., Riederer P. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease. Neurotoxicol. Res. 5:2003;35-44
2. Olanow C.W., Youdim M.B. Iron and neurodegeneration: prospects for neuroprotection. Olanow C.W., Jenner P., Youdim M.B. Neurodegeneration and neuroprotection in Parkinson's disease. 1996;55-69 Academic Press, London
3. Mandel S., Grunblatt E., Youdim M.B.H. cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease. J. Neural Transm. Suppl. 60:2000;117-124
4. Linazasoro G. Neuroprotection in Parkinson's disease: love story or mission impossible? Expert Rev. Neurother. 2:2002;403-416
5. Vila M., Przedborski S. Targeting programmed cell death in neurodegenerative diseases. Nat. Rev. Neurosci. 4:2003;365-375
6. Mandel S., Weinreb O., Youdim M.B. Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs. Trends Pharmacol. Sci. 24:2003;184-191
7. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65:2001;135-172
8. Slikker W., Youdim M.B., Palmer G.C., Hall E., Williams C., Trembly B. The future of neuroprotection. Ann. N. Y. Acad. Sci. 890:1999;529-533
9. Salah N., Miller N.J., Paganga G., Tijburg L., Bolwell G.P., Rice-Evans C. Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Arch. Biochem. Biophys. 322:1995;339-346
10. Nanjo F., Goto K., Seto R., Suzuki M., Sakai M., Hara Y. Scavenging effects of tea catechins and their derivatives on 1, 1-diphenyl-2-picrylhydrazyl radical. Free Radic. Biol. Med. 21:1996;895-902
11. Guo Q., Zhao B., Li M., Shen S., Xin W. Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes. Biochim. Biophys. Acta. 1304:1996;210-222
12. Pan M.H., Lin-Shiau S.Y., Ho C.T., Lin J.H., Lin J.K. Suppression of lipopolysaccharide-induced nuclear factor kappaB activity by theaflavin-3, 3′-digallate from black tea and other polyphenols through down-regulation of IkappaB kinase activity in macrophages. Biochem. Pharmacol. 59:2000;357-367
13. Haqqi T.M., Anthony D.D., Gupta S., Ahmad N., Lee M.S., Kumar G.K., Mukhtar H. Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc. Natl. Acad. Sci. USA. 96:1999;4524-4529
14. Wang Z.Y., Huang M.T., Lou Y.R., Xie J.G., Reuhl K.R., Newmark H.L., Ho C.T., Yang C.S., Conney A.H. Inhibitory effects of black tea, green tea, decaffeinated black tea, and decaffeinated green tea on ultraviolet B light-induced skin carcinogenesis in 7, 12-dimethylbenz[a]anthracene-initiated SKH-1 mice. Cancer Res. 54:1994;3428-3455
15. Yang C.S., Wang Z.Y. Tea and cancer. J. Natl. Cancer Inst. 85:1993;1038-1049
16. Higdon J.V., Frei B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit. Rev. Food Sci. Nutr. 43:2003;89-143
17. Lin Y.L., Tsai S.H., Lin-Shiau S.Y., Ho C.T., Lin J.K. Theaflavin-3, 3′-digallate from black tea blocks the nitric oxide synthase by down-regulating the activation of NF-kappaB in macrophages. Eur. J. Pharmacol. 367:1999;379-388
18. Lin J.K., Liang Y.C., Lin-Shiau S.Y. Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade. Biochem. Pharmacol. 58:1999;911-915
19. Ishige K., Schubert D., Sagara Y. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic. Biol. Med. 30:2001;433-446
20. Schroeter H., Boyd C., Spencer J.P., Williams R.J., Cadenas E., Rice-Evans C. MAPK signaling in neurodegeneration: influences of flavonoids and of nitric oxide. Neurobiol. Aging. 23:2002;861-880
21. Chung J.H., Han J.H., Hwang E.J., Seo J.Y., Cho K.H., Kim K.H., Youn J.I., Eun H.C. Dual mechanisms of green tea extract-induced cell survival in human epidermal keratinocytes. FASEB J. 17:2003;1913-1915
22. Chen C., Yu R., Owuor E.D., Kong A.N. Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. Arch. Pharm. Res. 23:2000;605-612
23. Lorenz M., Wessler S., Follmann E., Michaelis W., Dusterhoft T., Baumann G., Stangl K., Stangl V. A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a PI3K-, PKA-, and Akt-dependent pathway, and leads to endothelial-dependent vasorelaxation. J. Biol. Chem. 279:2003;6190-6195
24. Levites Y., Amit T., Youdim M.B.H., Mandel S. Involvement of protein kinase C activation and cell survival/cell cycle genes in green tea polyphenol (-)-epigallocatechin-3-gallate neuroprotective action. J. Biol. Chem. 277:2002;30574-30580
25. Levites Y., Amit T., Mandel S., Youdim M.B.H. Neuroprotection and neurorescue against amyloid beta toxicity and PKC-dependent release of non-amyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J. 17:2003;952-954
26. Weinreb O., Mandel S., Youdim M.B. Gene and protein expression profiles of anti- and pro-apoptotic actions of dopamine, R-apomorphine, green tea polyphenol (-)-epigallocatechine-3-gallate, and melatonin. Ann. N. Y. Acad. Sci. 993:2003;351-361. (discussion 387-393)
27. Ono K., Yoshiike Y., Takashima A., Hasegawa K., Naiki H., Yamada M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J. Neurochem. 87:2003;172-181
28. Schroeter H., Spencer J.P., Rice-Evans C., Williams R.J. Flavonoids protect neurons from oxidized low-density-lipoprotein-induced apoptosis involving c-Jun N-terminal kinase (JNK), c-Jun and caspase-3. Biochem. J. 358:2001;547-557
29. Nobre Junior H.V., Cunha G.M., Maia F.D., Oliveira R.A., Moraes M.O., Rao V.S. Catechin attenuates 6-hydroxydopamine (6-OHDA)-induced cell death in primary cultures of mesencephalic cells. Comp. Biochem. Physiol. C. 136:2003;175-180
30. Choi Y.T., Jung C.H., Lee S.R., Bae J.H., Baek W.K., Suh M.H., Park J., Park C.W., Suh S.I. The green tea polyphenol (-)-epigallocatechin gallate attenuates beta-amyloid-induced neurotoxicity in cultured hippocampal neurons. Life Sci. 70:2001;603-614
31. Mandel S., Reznichenko L., Amit T., Youdim M. Green tea polyphenol (-)-epigallocatechin-3-gallate protects rat PC12 cells from apoptosis induced by serum withdrawal independent of P13-Akt pathway. Neurotoxicol. Res. 5:2003;419-424
32. Rice-Evans C. Implications of the mechanisms of action of tea polyphenols as antioxidants in vitro for chemoprevention in humans. Proc. Soc. Exp. Biol. Med. 220:1999;262-266
33. Levites Y., Youdim M.B.H., Maor G., Mandel S. Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. Biochem. Pharmacol. 63:2002;21-29
34. Rice-Evans C.A., Miller N.J., Bolwell P.G., Bramley P.M., Pridham J.B. The relative antioxidant activities of plant-derived polyphenolic flavonoids. Free Radic. Res. 22:1995;375-383
35. Hider R.C., Liu Z.D., Khodr H.H. Metal chelation of polyphenols. Methods Enzymol. 335:2001;190-203
36. Kumamoto M., Sonda T., Nagayama K., Tabata M. Effects of pH and metal ions on antioxidative activities of catechins. Biosci. Biotechnol. Biochem. 65:2001;126-132
37. Grinberg L.N., Newmark H., Kitrossky N., Rahamim E., Chevion M., Rachmilewitz E.A. Protective effects of tea polyphenols against oxidative damage to red blood cells. Biochem. Pharmacol. 54:1997;973-978
38. Levites Y., Weinreb O., Maor G., Youdim M.B.H., Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced dopaminergic neurodegeneration. J. Neurochem. 78:2001;1073-1082
39. Komatsu M., Hiramatsu M. The efficacy of an antioxidant cocktail on lipid peroxide level and superoxide dismutase activity in aged rat brain and DNA damage in iron-induced epileptogenic foci. Toxicology. 148:2000;143-148
40. Owuor E.D., Kong A.N. Antioxidants and oxidants regulated signal transduction pathways. Biochem. Pharmacol. 64:2002;765-770
41. LeVine S.M., Connor J.R., Schipper H.M. Redox-active metals in neurological disorders. Ann. N. Y. Acad. Sci. 1012:2004;New York Academy of Sciences, New York
42. Gerlach M., Ben-Shachar D., Riederer P., Youdim M.B. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63:1994;793-807
43. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B.H. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52:1989;515-520
44. Jellinger K.A. Neuropathological spectrum of synucleinopathies. Mov. Disord. 18(Suppl. 6):2003;S2-S12
45. Maroteaux L., Scheller R.H. The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Brain Res. Mol. Brain Res. 11:1991;335-343
46. Clayton D.F., George J.M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 21:1998;249-254
47. Lavedan C. The synuclein family. Genome Res. 8:1998;871-880
48. Turnbull S., Tabner B.J., El-Agnaf O.M., Moore S., Davies Y., Allsop D. Alpha-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. Free Radic. Biol. Med. 30:2001;1163-1170
49. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J.M., Farer M., Wolozin B. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J. Neurosci. 20:2000;6048-6054
50. Ebadi M., Govitrapong P., Sharma S., Muralikrishnan D., Shavali S., Pellett L., Schafer R., Albano C., Eken J. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of Parkinson's disease. Biol. Signals Recept. 10:2001;224-253
51. Vila M., Vukosavic S., Jackson-Lewis V., Neystat M., Jakowec M., Przedborski S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 74:2000;721-729
52. Mandel S., Maor G., Youdim M.B.H. Iron and alpha synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol epigallocatechin-3-gallate. J. Mol. Neurosci. 2004
53. Hashimoto M., Takeda A., Hsu L.J., Takenouchi T., Masliah E. Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease. J. Biol. Chem. 274:1999;28849-28852
54. Ben-Shachar D., Eshel G., Finberg J.P., Youdim M.B. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56:1991;1441-1444
55. Lan J., Jiang D.H. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural. Transm. (Budapest). 104:1997;469-481
56. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J.Q., Boonplueang R., Viswanath V., Jacobs R., Yang L., Beal M.F., DiMonte D., Volitaskis I., Ellerby L., Cherny R.A., Bush A.I., Andersen J.K. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron. 37:2003;899-909
57. Rubinstein M., Dupont P., Doppee J.P., Dehon C., Ducobu J., Hainaut J. Ocular toxicity of desferrioxamine. Lancet. 1:1985;817-818
58. Shachar D.B., Kahana N., Kampel V., Warshawsky A., Youdim M.B. Neuroprotection by a novel brain permeable iron chelator. VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology. 46:2004;254-263
59. Youdim M.B.H., Stephenson G., Ben-Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators; a lesson from 6-hydroxydopamine and iron chelators desferal and vk-28. Ann. N. Y. Acad. Sci. 2004
60. Weinreb O., Mandel S., Youdim M.B.H. cDNA gene expression profile homology of antioxidants and their anti-apoptotic and pro-apoptotic activities in human neuroblastoma cells. FASEB J. 17:2003;935-937
61. Merry D.E., Korsmeyer S.J. Bcl-2 gene family in the nervous system. Annu. Rev. Neurosci. 20:1997;245-267
62. Mattson M.P., Kroemer G. Mitochondria in cell death: novel targets for neuroprotection and cardioprotection. Trends Mol. Med. 9:2003;196-205
63. DeFeudis F.V., Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr. Drug Targets. 1:2000;25-58
64. Medina J.H., Viola H., Wolfman C., Marder M., Wasowski C., Calvo D., Paladini A.C. Overview - flavonoids: a new family of benzodiazepine receptor ligands. Neurochem. Res. 22:1997;419-425
65. Huen M.S., Hui K.M., Leung J.W., Sigel E., Baur R., Wong J.T., Xue H. Naturally occurring 2′-hydroxyl-substituted flavonoids as high-affinity benzodiazepine site ligands. Biochem. Pharmacol. 66:2003;2397-2407
66. Beal M.F. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann. Neurol. 53(Suppl. 3):2003;S39-S47. (discussion S47-48)
67. Tachibana H., Koga K., Fujimura Y., Yamada K. A receptor for green tea polyphenol EGCG. Nat. Struct. Mol. Biol. 2004
68. Masuda M., Suzui M., Weinstein I.B. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin. Cancer Res. 7:2001;4220-4229
69. Hastak K., Gupta S., Ahmad N., Agarwal M.K., Agarwal M.L., Mukhtar H. Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene. 22:2003;4851-4859
70. Hofmann C.S., Sonenshein G.E. Green tea polyphenol epigallocatechin-3 gallate induces apoptosis of proliferating vascular smooth muscle cells via activation of p53. FASEB J. 17:2003;702-704
71. Berra E., Municio M.M., Sanz L., Frutos S., Diaz-Meco M.T., Moscat J. Positioning atypical protein kinase C isoforms in the UV-induced apoptotic signaling cascade. Mol. Cell. Biol. 17:1997;4346-4354
72. Liu W.S., Heckman C.A. The sevenfold way of PKC regulation. Cell Signalling. 10:1998;529-542
73. Dempsey E.C., Newton A.C., Mochly-Rosen D., Fields A.P., Reyland M.E., Insel P.A., Messing R.O. Protein kinase C isozymes and the regulation of diverse cell responses. Am. J. Physiol. Lung Cell. Mol. Physiol. 279:2000;L429-L438
74. Maher P. How protein kinase C activation protects nerve cells from oxidative stress-induced cell death. J. Neurosci. 21:2001;2929-2938
75. Cordey M., Gundimeda U., Gopalakrishna R., Pike C.J. Estrogen activates protein kinase C in neurons: role in neuroprotection. J. Neurochem. 84:2003;1340-1348
76. Murriel C.L., Mochly-Rosen D. Opposing roles of delta and epsilonPKC in cardiac ischemia and reperfusion: targeting the apoptotic machinery. Arch. Biochem. Biophys. 420:2003;246-254
77. Ruvolo P.P., Deng X., Carr B.K., May W.S. A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis. J. Biol. Chem. 273:1998;25436-25442
78. Gubina E., Rinaudo M.S., Szallasi Z., Blumberg P.M., Mufson R.A. Overexpression of protein kinase C isoform epsilon but not delta in human interleukin-3-dependent cells suppresses apoptosis and induces bcl-2 expression. Blood. 91:1998;823-829
79. Whelan R.D., Parker P.J. Loss of protein kinase C function induces an apoptotic response. Oncogene. 16:1998;1939-1944
80. Xia Z., Dickens M., Raingeaud J., Davis R.J., Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 270:1995;1326-1331
81. Singer C.A., Figueroa-Masot X.A., Batchelor R.H., Dorsa D.M. The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J. Neurosci. 19:1999;2455-2463
82. Kaplan D.R., Miller F.D. Neurotrophin signal transduction in the nervous system. Curr. Opin. Neurol. 10:2000;381-391
83. Kermer P., Klocker N., Labes M., Bahr M. Insulin-like growth factor-I protects axotomized rat retinal ganglion cells from secondary death via PI3-K-dependent Akt phosphorylation and inhibition of caspase-3 in vivo. J. Neurosci. 20:2000;2-8
84. Gary D.S., Milhavet O., Camandola S., Mattson M.P. Essential role for integrin linked kinase in Akt-mediated integrin survival signaling in hippocampal neurons. J. Neurochem. 84:2003;878-890
85. Vaudry D., Stork P.J., Lazarovici P., Eiden L.E. Signaling pathways for PC12 cell differentiation: making the right connections. Science. 296:2002;1648-1649
86. Johnson G.L., Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 298:2002;1911-1912
87. Checkoway H., Powers K., Smith-Weller T., Franklin G.M., Longstreth W.T. Jr., Swanson P.D. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am. J. Epidemiol. 155:2002;732-738
88. Matsuoka Y., Hasegawa H., Okuda S., Muraki T., Uruno T., Kubota K. Ameliorative effects of tea catechins on active oxygen-related nerve cell injuries. J. Pharmacol. Exp. Ther. 274:1995;602-608
89. Lee S., Suh S., Kim S. Protective effects of the green tea polyphenol (-)-epigallocatechin gallate against hippocampal neuronal damage after transient global ischemia in gerbils. Neurosci. Lett. 287:2000;191-194
90. Sweeney M.I., Kalt W., MacKinnon S.L., Ashby J., Gottschall-Pass K.T. Feeding rats diets enriched in lowbush blueberries for six weeks decreases ischemia-induced brain damage. Nat. Neurosci. 5:2002;427-431
91. Pan T., Fei J., Zhou X., Jankovic J., Le W. Effects of green tea polyphenols on dopamine uptake and on MPP+-induced dopamine neuron injury. Life Sci. 72:2003;1073-1083
92. Lu H., Meng X., Yang C.S. Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (-)-epigallocatechin gallate. Drug Metab. Dispos. 31:2003;572-579
93. Deleu D., Northway M.G., Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin. Pharmacokinet. 41:2002;261-309
94. Commenges D., Scotet V., Renaud S., Jacqmin-Gadda H., Barberger-Gateau P., Dartigues J.F. Intake of flavonoids and risk of dementia. J. Epidemiol. 16:2000;357-363
95. Le Bars P.L., Kieser M., Itil K.Z. A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia. Dement. Geriatr. Cognit. Disord. 11:2000;230-237
96. Youdim K.A., Spencer J.P., Schroeter H., Rice-Evans C. Dietary flavonoids as potential neuroprotectants. Biol. Chem. 383:2002;503-519
97. Pratico D., Delanty N. Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am. J. Med. 109:2000;577-585
98. Patil C.S., Singh V.P., Satyanarayan P.S., Jain N.K., Singh A., Kulkarni S.K. Protective effect of flavonoids against aging- and lipopolysaccharide- induced cognitive impairment in mice. Pharmacology. 69:2003;59-67
99. Ahlemeyer B., Krieglstein J. Neuroprotective effects of Ginkgo biloba extract. Cell. Mol. Life Sci. 60:2003;1779-1792
100. Galli R.L., Shukitt-Hale B., Youdim K.A., Joseph J.A. Fruit polyphenolics and brain aging: nutritional interventions targeting age-related neuronal and behavioral deficits. Ann. N. Y. Acad. Sci. 959:2002;128-132
101. Youdim K.A., Joseph J.A. A possible emerging role of phytochemicals in improving age-related neurological dysfunctions: a multiplicity of effects. Free Radic. Biol. Med. 30:2001;583-594
102. Kumari M.V., Yoneda T., Hiramatsu M. Effect of "beta CATECHIN" on the life span of senescence accelerated mice (SAM-P8 strain). Biochem. Mol. Biol. Int. 41:1997;1005-1011
103. Joseph J.A., Shukitt-Hale B., Denisova N.A., Bielinski D., Martin A., McEwen J.J., Bickford P.C. Reversals of age-related declines in neuronal signal transduction, cognitive, and motor behavioral deficits with blueberry, spinach, or strawberry dietary supplementation. J. Neurosci. 19:1999;8114-8121
104. Joseph J.A., Denisova N.A., Arendash G., Gordon M., Diamond D., Shukitt-Hale B., Morgan D. Blueberry supplementation enhances signaling and prevents behavioral deficits in an Alzheimer disease model. Nat. Neurosci. 6:2003;153-162
105. Stackman R.W., Eckenstein F., Frei B., Kulhanek D., Nowlin J., Quinn J.F. Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Exp. Neurol. 184:2003;510-520
106. Bush A.I. The metallobiology of Alzheimer's disease. Trends Neurosci. 26:2003;207-214
107. Selkoe D.J. Amyloid beta protein and the genetics of Alzheimer's disease. J. Biol. Chem. 271:1996;18295-18298
108. Selkoe D.J. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell. Biol. 8:1998;447-453
109. Mills J., Reiner P.B. Regulation of amyloid precursor protein cleavage. J. Neurochem. 72:1999;443-460
110. Mattson M.P., Barger S.W., Furukawa K., Bruce A.J., Wyss-Coray T., Mark R.J., Mucke L. Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease. Brain Res. Brain Res. Rev. 23:1997;47-61
111. Xu X., Yang D., Wyss-Coray T., Yan J., Gan L., Sun Y., Mucke L. Wild-type but not Alzheimer-mutant amyloid precursor protein confers resistance against p53-mediated apoptosis. Proc. Natl. Acad. Sci. USA. 96:1999;7547-7552
112. Small D.H., Nurcombe V., Reed G., Clarris H., Moir R., Beyreuther K., Masters C.L. A heparin-binding domain in the amyloid protein precursor of Alzheimer's disease is involved in the regulation of neurite outgrowth. J. Neurosci. 14:1994;2117-2127
113. Morimoto T., Ohsawa I., Takamura C., Ishiguro M., Kohsaka S. Involvement of amyloid precursor protein in functional synapse formation in cultured hippocampal neurons. J. Neurosci. Res. 51:1998;185-195
114. Haass C., Mandelkow E. Proteolysis by presenilins and the renaissance of tau. Trends Cell. Biol. 9:1999;241-244
115. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:2000;916-919
116. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., Barnham K.J., Volitakis I., Fraser F.W., Kim Y., Huang X., Goldstein L.E., Moir R.D., Lim J.T., Beyreuther K., Zheng H., Tanzi R.E., Masters C.L., Bush A.I. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 30:2001;665-676
117. Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., Kiers L., Cherny R., Li Q.X., Tammer A., Carrington D., Mavros C., Volitakis I., Xilinas M., Ames D., Davis S., Beyreuther K., Tanzi R.E., Masters C.L. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60:2003;1685-1691
118. Avramovich Y., Amit T., Youdim M.B. Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein. J. Biol. Chem. 277:2002;31466-31473
119. Yogev-Falach M., Amit T., Bar-Am O., Youdim M.B. The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. FASEB J. 17:2003;2325-2327
120. Rich J.B., Rasmusson D.X., Folstein M.F., Carson K.A., Kawas C., Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology. 45:1995;51-55
121. Breitner J.C., Welsh K.A., Helms M.J., Gaskell P.C., Gau B.A., Roses A.D., Pericak-Vance M.A., Saunders A.M. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol. Aging. 16:1995;523-530
122. Seo J.H., Rah J.C., Choi S.H., Shin J.K., Min K., Kim H.S., Park C.H., Kim S., Kim E.M., Lee S.H., Lee S., Suh S.W., Suh Y.H. α-Synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J. 5:2002;5
123. Yankner B.A., Duffy L.K., Kirschner D.A. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science. 250:1990;279-282
124. Luo Y., Sunderland T., Wolozin B. Physiologic levels of beta-amyloid activate phosphatidylinositol 3-kinase with the involvement of tyrosine phosphorylation. J. Neurochem. 67:1996;978-987
125. Atwood C.S., Obrenovich M.E., Liu T., Chan H., Perry G., Smith M.A., Martins R.N. Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta. Brain Res. Brain Res. Rev. 43:2003;1-16
126. Senior K. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol. 1:2002;3
127. Aronowski J., Strong R., Shirzadi A., Grotta J.C. Ethanol plus caffeine (caffeinol) for treatment of ischemic stroke: preclinical experience. Stroke. 34:2003;1246-1251
128. Khaldy H., Escames G., Leon J., Bikjdaouene L., Acuna-Castroviejo D. Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DA depletion. Neurobiol. Aging. 24:2003;491-500
129. Conte A., Pellegrini S., Tagliazucchi D. Synergistic protection of PC12 cells from beta-amyloid toxicity by resveratrol and catechin. Brain Res. Bull. 62:2003;29-38
130. Kyriazis M. Neuroprotective, anti-apoptotic effects of apomorphine. J. Anti Aging Med. 6:2003;21-28
131. Felletschin B., Bauer P., Walter U., Behnke S., Spiegel J., Csoti I., Sommer U., Zeiler B., Becker G., Riess O., Berg D. Screening for mutations of the ferritin light and heavy genes in Parkinson's disease patients with hyperechogenicity of the substantia nigra. Neurosci. Lett. 352:2003;53-56
132. Youdim M.B.H., Riederer P. Iron in the brain, normal and pathological. Adelman G., Smith B. Encyclopedia of Neuroscience. 2004
133. Gunshin H., Mackenzie B., Berger U.V., Gunshin Y., Romero M.F., Boron W.F., Nussberger S., Gollan J.L., Hediger M.A. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature. 388:1997;482-488
134. Harada M., Kan Y., Naoki H., Fukui Y., Kageyama N., Nakai M., Miki W., Kiso Y. Identification of the major antioxidative metabolites in biological fluids of the rat with ingested (+)-catechin and (-)-epicatechin. Biosci. Biotechnol. Biochem. 63:1999;973-977
135. Spencer J.P., Schroeter H., Kuhnle G., Srai S.K., Tyrrell R.M., Hahn U., Rice-Evans C. Epicatechin and its in vivo metabolite, 3′-O-methyl epicatechin, protect human fibroblasts from oxidative-stress-induced cell death involving caspase-3 activation. Biochem. J. 354:2001;493-500